UVX as an Adjuvant in the Treatment of Fungal Keratitis

Not Applicable

• Conditions: Treatment
• Interventions: Drug: topical voriconazole / levofloxacin systemic itraconazole; Radiation: CXL

• Registration Number: NCT03138785
• Lead Sponsor: Farabi Eye Hospital

Brief Summary

In this study, investigators want to find the effect of adjuvant collagen cross-linking in the treatment of fungal keratitis

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-01
• Study First Submitted: 2017-02-22
• Status Verified: 2017-04
• Study First Submitted QC: 2017-04-29
• Last Update Submitted: 2017-04-29
• Study First Posted: 2017-05-03
• Last Update Posted: 2017-05-03
• Primary Completion: 2017-06-01
• Study Completion: 2017-07-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• fungal keratitis documented by culture or confocal scanning without any previous treatment

Exclusion Criteria

• Previous treatment
• Thinning at presentation
• Perforation
• Associated with other microbial or viral keratitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
conventional treatment +CXL	CXL	In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
conventional treatment	topical voriconazole / levofloxacin systemic itraconazole	In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
conventional treatment +CXL	topical voriconazole / levofloxacin systemic itraconazole	In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day

Primary Outcome Measures

Name	Time	Method
time of complete healing (days)	180 days	time to scar formation (days)